Cerapedics Revenue and Competitors
Estimated Revenue & Valuation
- Cerapedics's estimated annual revenue is currently $41.1M per year.
- Cerapedics received $22.0M in venture funding in July 2018.
- Cerapedics's estimated revenue per employee is $236,063
- Cerapedics's total funding is $180.7M.
- Cerapedics has 174 Employees.
- Cerapedics grew their employee count by 60% last year.
What Is Cerapedics?
Cerapedics is an advanced orthobiologics company focused on developing its proprietary biomimetic small peptide molecule (P-15) for commercialization in spinal applications. i-FACTOR Peptide Enhanced Bone Graft (P-15/ABM) is only the 2nd FDA PMA Approve bone graft on the market, and it has shown statistical superiority to local autograft through an IDE trial on single-level ACDFs in overall clinical success at one year. i-FACTOR is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action (Attract, Attach, Activate) is designed to support safer and more predictable bone formation compared to other commercially available bone growth factors.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Cerapedics describes i-FACTOR as a peptide enhanced bone graft that will Attract, Attach, and Activate osteogenic cells to build bone...
WESTMINSTER, Colo., Aug. 17, 2021 /PRNewswire/ -- Cerapedics Inc., a private ortho-biologics company dedicated to enhancing the science of bone repair, announced today that results of a study to evaluate the cost-effectiveness of i-FACTOR Peptide Enhanced Bone Graft compared to autograft for p ...
WESTMINSTER, Colo., April 29, 2021 /PRNewswire/ -- Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graf ...
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ -- Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada. "We are excited to ...
Cerapedics, a private ortho-biologics company, plans an expansion of the company's headquarters located in metro Denver, Colorado.
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|2012-12-13||$19.0M||C||MedImmune Ventures, CVF LLC||Article|